Patent intelligence · US
US 11202822
Methods for treating hypophosphatemic disorders
Methods for treating hypophosphatemic disorders
Patent details — US 11202822
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 21, 2021
- Expiration
- Dec 16, 2041
- Applicant
- Ultragenyx Pharmaceutical Inc.
- Claims
- 9
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K2039/545
Quick answer
US 11202822 (Methods for treating hypophosphatemic disorders) is held by Ultragenyx Pharmaceutical Inc.. Status: granted. Granted Dec 21, 2021. Expires Dec 16, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Ultragenyx Pharmaceutical Inc.
- Grant date
- Expiration
- Claims
- 9
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K39/001132, A61P
More from Ultragenyx Pharmaceutical Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12358976
Methods for increasing serum concentration of phosphorous and/or 1,25-hydroxy vitamin d
granted -
US 12338450
Gene therapy constructs for treating Wilson disease
granted -
US 11944658
Methods of heat inactivation of adenovirus
granted -
US 11771748
Methods for treating tumor-induced osteomalacia
granted -
US 11753369
Creatine prodrugs, compositions and methods of use thereof
granted -
US 11377643
Therapeutics for glycogen storage disease type III
granted -
US 11332438
Creatine prodrugs, compositions and methods of use thereof
granted
Frequently asked questions
What is US patent 11202822?
US 11202822 (Methods for treating hypophosphatemic disorders) is held by Ultragenyx Pharmaceutical Inc.. Status: granted. Granted Dec 21, 2021. Expires Dec 16, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11202822?
Ultragenyx Pharmaceutical Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 23 pharmaceutical patents for this assignee.
When does US 11202822 expire?
Our index shows an expiration date of Dec 16, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.